Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

165.86 +1.63 (+0.99%)
Official Closing Price Updated: 7:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,971,064
Open 164.12
Bid (Size) 165.52 (3)
Ask (Size) 165.85 (1)
Prev. Close 164.23
Today's Range 163.81 - 165.98
52wk Range 143.13 - 165.98
Shares Outstanding 2,628,679,824
Dividend Yield 2.87%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyzing NYSE:JNJ's Dividend Potential.
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock. 
Via Chartmill
Is Johnson & Johnson the Best Dividend Stock for You?
You won't find a more dependable dividend payer on Wall Street. But whether it's the best stock for you depends on other factors. 
Via The Motley Fool

Performance

YTD
+3.68%
+3.68%
1 Month
+1.05%
+1.05%
3 Month
+12.26%
+12.26%
6 Month
+3.77%
+3.77%
1 Year
+3.22%
+3.22%

More News

Read More
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
Via The Motley Fool
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Aug. 30
Via Talk Markets
Will JOHNSON & JOHNSON Break Out? A Technical Analysis Perspective.
Via Chartmill
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Via Benzinga
Is Johnson & Johnson Stock a Buy?
Via The Motley Fool
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
Via Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Via Benzinga
Exposures Product Safety
12 Dividend Stocks to Earn Income Every Month
Via The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
Via The Motley Fool
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Via Benzinga
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Via Benzinga
Here Are 2 Great Vanguard Dividend ETFs: Which Is Right For You?
Via The Motley Fool
Topics ETFs
Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists
Via The Motley Fool
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
Via Benzinga
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
Via Benzinga
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
From Johnson & Johnson
Via Business Wire
2 Unstoppable Stocks That Are Screaming Buys in August
Via The Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
Via The Motley Fool
Topics Government
Exposures Political
A Big CEO Move, Big Buffett Buys, and More
Via The Motley Fool
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
Via The Motley Fool
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.